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Prevalence and determinants of human papillomavirus infection
and cervical lesions in HIV-positive women in Kenya
H De Vuyst*,1, NR Mugo2, MH Chung3,4,5, KP McKenzie3, E Nyongesa-Malava3, V Tenet1, JW Njoroge3,
SR Sakr6, CJLM Meijer7, PJF Snijders7, FS Rana8 and S Franceschi1
1International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372 Lyon Cedex 08, Lyon, France; 2Department of Obstetrics and
Gynecology, Kenyatta National Hospital, PO Box 19676, Off Ngong Road, Nairobi, Kenya; 3Department of Global Health, University of Washington, 325
Ninth Avenue, Seattle, WA 98104, USA; 4Department of Medicine, University of Washington, 325 Ninth Avenue, Seattle, WA 98104, USA; 5Department
of Epidemiology, University of Washington, 325 Ninth Avenue, Seattle, WA 98104, USA; 6Coptic Hospital, Coptic Hope Center, PO Box 21570-00505,
Nairobi, Kenya; 7Department of Pathology, Vrije Universiteit Medical Center, Postbus 7057, 1007 MB Amsterdam, The Netherlands; 8Department of
Pathology, Aga Khan University Hospital, 3rd Parklands Avenue, Nairobi, Kenya
BACKGROUND: We assessed the association of human papillomavirus (HPV) infection and cervical intraepithelial neoplasia (CIN) with
various characteristics, CD4 count and use of combination antiretroviral therapy (cART) among HIV-positive women.
METHODS: Cross-sectional study of 498 HIV-positive women who underwent HPV PCR-based testing, cytology, and systematic
cervical biopsy.
RESULTS: In all, 68.7% of women were HPV-positive, 52.6% had high-risk (hr) HPV, and 40.2% multiple type infections. High-risk human
papillomavirus-positivity did not vary significantly by age but it was negatively associated with education level. The most frequent types
in 113 CIN2/3 were HPV16 (26.5%), HPV35 (19.5%), and HPV58 (12.4%). CD4 count was negatively associated with prevalence of
hrHPV (Po0.001) and CIN2/3 among non-users of cART (P¼ 0.013). Combination antiretroviral therapies users (X2 year) had
lower hrHPV prevalence (prevalence ratio (PR) vs non-users¼ 0.77, 95% confidence interval (CI): 0.61–0.96) and multiple infections
(PR¼ 0.68, 95% CI: 0.53–0.88), but not fewer CIN2/3. The positive predictive value of hrHPV-positivity for CIN2/3 increased from
28.9% at age o35 years to 53.3% in X45 years.
CONCLUSION: The burden of hrHPV and CIN2/3 was high and it was related to immunosuppression level. Combination antiretroviral
therapies (X2 year) use had a favourable effect on hrHPV prevalence but cART in our population may have been started too late to
prevent CIN2/3.
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Women living with HIV are at increased risk for human
papillomavirus (HPV) infection and HPV-related tumours, includ-
ing cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) and
invasive cervical carcinoma (ICC) (Clifford et al, 2006; De Vuyst
et al, 2008). The prevalence of HPV and CIN has been reported to
increase with the increase of immunosuppression (Denny et al,
2008; Firnhaber et al, 2010). Combination antiretroviral therapies
(cART) against HIV have greatly reduced the incidence of
opportunistic infections, Kaposi’s sarcoma, and non-Hodgkin’s
lymphoma, but not the incidence of HPV-associated cervical and
anal carcinomas (Franceschi et al, 2010). This is perhaps not
surprising as HPV-associated carcinomas have a long latent phase.
A favourable effect of cART on HPV infection and cervical pre-
cancerous lesions has been shown in some (Paramsothy et al, 2009;
Minkoff et al, 2010), but not all studies (Bratcher and
Sahasrabuddhe, 2010; Shrestha et al, 2010) on the topic.
A favourable effect of cART on cervical cancer and its precursor
lesions would be of particular importance in sub-Saharan Africa
(SSA), home to three quarters of women living with HIV (WHO,
2011), and 14% of cervical cancer cases worldwide (Ferlay et al,
2010). Access to cART has recently been greatly improved in SSA
and by the end of 2010 nearly half of the people who need cART in
SSA have had access to it (WHO, 2011). Access to cervical
screening is also improving among HIV-positive women in SSA
(Brower, 2011), but to a much lesser extent than that to cART.
Human papillomavirus testing has been shown to be superior to
cytological screening in terms of sensitivity and duration of
negative predictive value against CIN2/3 and cervical cancer in the
general female population in high- and low-resource countries
(Sankaranarayanan et al, 2009; Ronco et al, 2010; Rijkaart et al,
2012). The use of HPV testing in HIV-positive women and, by and
large, in very high HPV prevalence populations have created,
however, concerns due to the low test specificity in these settings
(Giorgi-Rossi et al, 2012), and hence, the heavy burden of the
management of HPV-positive women (Kitchener et al, 2007).
Scanty data are available on the detection of high-grade lesions
through HPV testing in under-screened populations (Keita et al,
2009; Gage et al, 2012), including in HIV-positive women (Denny
et al, 2008; Singh et al, 2009).
The aims of this cross-sectional study from Nairobi, Kenya, were
to assess: (1) the distribution of different HPV types at baseline in
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a cohort of HIV-positive women; (2) the association of high-risk
(hr) HPV infection and CIN2/3 with various host factors, including
age, CD4 count, and cART use; and (3) the positive predictive
value (PPV) of HPV testing in HIV-positive women.
MATERIALS AND METHODS
Participants and study procedures
In 2009, 498 HIV-positive women in Nairobi, Kenya were included
as part of a study comparing cervical cancer screening methods.
Women who attended the Coptic Hope Center for Infectious
Diseases for HIV-related conditions were invited to participate in
the study and were eligible if they were: between 18 and 55 years of
age; not screened in the last year; and never treated for cervical
cancer or pre-cancerous lesions. Women received cervical cancer
screening with conventional cytology, visual inspection with acetic
acid, and HPV testing (Chung et al, 2011a, b). The characteristics
of these women at baseline are the object of the present report.
After obtaining a written informed consent, information on
clinical and lifestyle characteristics of study women was collected.
A venous blood sample was taken to measure CD4 count. Cervical
exfoliated cells were collected by a nurse using a Cervex-Brush
(Rovers Medical Devices, Oss, The Netherlands) and placed in
PreservCyt medium (Hologic, Marlborough, MA, USA) for HPV
testing. A medical doctor performed a colposcopic examination
and took a biopsy from all women, either from the most abnormal
area on the cervix identified by the colposcopic examination, or at
12 o’clock if no lesion was visualised, as this position is the most
frequent location for cervical lesions. Biopsy tissues were
immediately immersed in 10%-buffered formalin and transported
to the pathology laboratory, where they were embedded in
paraffin. Cervical disease status in this study was based on biopsy
results. Twenty-seven women with inadequate biopsy results had,
therefore, to be excluded in the analyses that included histological
findings (Tables 1, 4 and 5).
As per Kenyan national guidelines, free cART should have
started if: (1) CD4 count was o250 cells ml 1; (2) World Health
Organisation (WHO) clinical stage was IV; (3) CD4 count was
o350 cells ml 1 and WHO clinical stage was III (Ojoo, 2007).
However, full information on history of cART use, CD4 count at
beginning of cART, and adherence to treatment was not available
in the present study.
The study protocol was approved by the Ethical Review
Committees of the Kenyatta National Hospital, Kenya, the
University of Washington, USA, and the International Agency
for Research on Cancer, France.
Human papillomavirus DNA testing
Human papillomavirus samples were stored at ambient tempera-
ture and shipped to the Department of Pathology of the Vrije
University Medical Centre, Amsterdam, The Netherlands for HPV
DNA testing. Testing was done on exfoliated cells, according to a
protocol similar to that used in previous IARC HPV prevalence
surveys (Clifford et al, 2005). Beta-globin polymerase chain
reaction (PCR) analysis was performed in order to assess the
DNA quality. The presence of HPV DNA was first determined
using general primer GP5þ /6þ -mediated PCR (Jacobs et al,
2000). Polymerase chain reaction products were hybridised using
an enzyme immunoassay (EIA) that included two oligoprobes: one
for hrHPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and
68 and another for low-risk HPV types 6, 11, 26, 30, 32, 34, 40, 42,
43, 44, 53, 54, 55, 57, 61, 64, 67, 69, 70, 71, 72, 73, 81, 82/mm4, 82/
is39, 83, 84, 85, 86, 89, and 90. Subsequent HPV typing was
performed by reverse-line blot hybridisation of PCR products, as
described previously (van den Brule et al, 2002). Human
papillomavirus types of IARC classification group 1 ‘carcinogenic
to humans’ (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59)
and group 2A ‘probably carcinogenic to humans’ (HPV68) were
considered as hr types (Schiffman et al, 2009). All other HPV types
were considered low-risk types. Samples that were positive at hr
EIA, but did not reveal positivity in the typing assay were classified
as uncharacterised hrHPV types. One sample was negative for
beta-globin, but positive for HPV DNA, and hence remained
included in the analysis.
Cytology and histology
Cytological slides and biopsies were processed by staff under the
supervision of the study pathologist (FR) at the Aga Khan
University of Nairobi, who also read all of the cytological and
histological slides. Cytology was reported according to the
Bethesda 1991 revised classification (Luff, 1992).
Statistical analysis
Prevalence ratios (PRs) and corresponding 95% confidence
intervals (CIs) of HPV infection by different characteristics were
computed using a binomial regression model with a log link (as
opposed to the logistic link used to compute odds ratios) adjusted
for age group (o30; 30–34; 35–39; 40–44; X45). Prevalence ratios
Table 1 Prevalence of HPV infection and individual HPV types by
histological findings and overall among 498 HIV-positive women (Kenya,
2009)
Normal
cervix
(N¼ 172)a
CIN1
(N¼ 186)a
CIN2/3
(N¼ 113)a
Overall
(N¼498)
HPV type n % n % n % s/m %
Negative 68 39.5 67 36.0 11 9.7 156 31.3
Positive 104 60.5 119 64.0 102 90.3 142/200 68.7
High-risk HPVþ 75 43.6 80 43.0 93 82.3 86/176 52.6
Low-risk HPVþ 67 39.0 80 43.0 71 62.8 56/173 46.0
High-risk
16/18 14 8.1 24 12.9 39 34.5 22/56 15.7
16 5 2.9 18 9.7 30 26.5 13/41 10.8
18 9 5.2 6 3.2 12 10.6 9/18 5.4
31 9 5.2 4 2.2 12 10.6 10/16 5.2
33 0 0.0 10 5.4 5 4.4 6/12 3.6
35 17 9.9 17 9.1 22 19.5 13/48 12.3
39 4 2.3 2 1.1 8 7.1 3/12 3.0
45 7 4.1 7 3.8 11 9.7 3/22 5.0
51 4 2.3 8 4.3 7 6.2 0/20 4.0
52 13 7.6 12 6.5 11 9.7 6/30 7.2
56 11 6.4 9 4.8 10 8.9 7/25 6.4
58 3 1.7 8 4.3 14 12.4 10/17 5.4
59 0 0.0 1 0.5 4 3.5 1/5 1.2
68 5 2.9 3 1.6 2 1.8 2/8 2.0
HRX 4 2.3 3 1.6 0 0.0 3/4 1.4
Low-risk
6 5 2.9 3 1.6 6 5.3 1/13 2.8
11 0 0.0 1 0.5 1 0.9 0/2 0.4
Other low-riskb 62 36.1 76 40.9 64 56.6 55/158 42.8
Multiple infection 55 32.0 65 35.0 72 63.7 —/200 40.2
Including high-risk
HPV
44 25.6 53 28.5 71 62.8 —/176 35.3
Including low-risk
HPV only
11 6.4 12 6.5 1 0.9 —/24 4.8
Abbreviations: CIN¼ cervical intraepithelial neoplasia; HIV¼ human immunodefi-
ciency virus; HPV¼ human papillomavirus; HRX¼ uncharacterised high-risk types;
s/m¼ number of single and multiple type infections. aExcluding 27 inadequate
histology results. bHPV infections including low-risk types other than 6 and/or 11.
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for HPV infection (any hr types and multiple types) and CIN2/3
were computed by cART use and by CD4 count (overall and
stratified by cART use). Prevalence ratios for CIN1 and CIN2/3
among hrHPV-positive women by the age groups were computed
with adjustment for CD4 (o250; 250–499; X500 cells ml 1), cART
use (never,o2 years,X2 years), and previous screening. Tests for
linear trend of PRs were computed giving an increasing score for
each level of the categorised variable and fitting them into the
model as continuous variables.
RESULTS
The mean age of 498 study women was 38.1 years (5–95%
percentiles: 27–51). Among women with adequate biopsy results,
172 (36.5%) had a normal histology. Cervical intraepithelial
neoplasia 1 was detected in 186 women (39.5%); CIN2 in 66
(14.0%); and CIN3 in 47 (10.0%). No ICCs were found.
Table 1 shows the prevalence of HPV types by histological
findings and overall. In total, 68.7% of women were HPV-positive,
52.6% were infected with hrHPV types, and 40.2% had multiple
infections. High-risk human papillomavirus types were found in
88.0% of multiple infections. Human papillomavirus prevalence
was 90.3% in women with CIN2/3. The most frequently found HPV
types among women with normal histology were HPV35 (9.9%),
HPV52 (7.6%), HPV56 (6.4%), HPV18, and HPV31 (both 5.2%).
The prevalence of individual HPV types in women with CIN1 was
similar as among women with normal histology, except for an
excess of HPV16. HPV16 (26.5%), HPV35 (19.5%), HPV58
(12.4%), and HPV18 and HPV31 (both 10.6%) were the most
frequently detected types in women with CIN2/3.
Prevalence ratios for hrHPV-positivity by selected character-
istics are shown in Table 2. High-risk human papillomavirus
prevalence decreased only slightly with age from 61.3% in women
o30 years to 49.5% in women X45 years (Ptrend PR¼ 0.136).
Women with higher education had a significantly lower
HPV prevalence, compared with women with primary education
only or no education (PR¼ 0.74; 95% CI: 0.58–0.95). Positivity for
hrHPV was not associated with marital status, number of lifetime
or recent partners, use of hormonal contraceptives or number of
pregnancies. All findings in Table 2 were similar when positivity
for any HPV instead of hrHPV types was assessed.
Figure 1 shows age-specific prevalence of HPV (classified
hierarchically into HPV16 and/or 18, hrHPV types but not HPV
16/18, and low-risk types only), and of multiple HPV infections.
No significant trends in positivity for HPV 16/18, other hr, low-
risk types, and multiple infections were found by age group.
CD4 count at recruitment was 407, 333, and 483 cells ml 1, in
women who had never used cART or had used cART foro2 years,
or X2 years, respectively (data not shown). The presence of
hrHPV infection according to CD4 count (overall and stratified by
cART use) and cART use is shown in Table 3. High-risk human
papillomavirus-positivity was higher in women with CD4 counts
o250 cells ml 1 (PR vs CD4 counts X500 cells ml 1¼ 1.46; 95%
CI: 1.18–1.82). The association of CD4 count with hrHPV-
positivity was similar in cART users and non-users, although
linear trend was significant among cART non-users only.
Compared with non-users, cART users for 2 years or longer were
less likely to be hrHPV-positive (PR¼ 0.77, 95% CI: 0.61–0.96).
Multiple HPV infections were also more frequent in women with
CD4 count o250 cellsml 1 (PR vs CD4 count X500 cells ml 1
¼ 1.89; 95% CI: 1.43–2.50), and less frequent in women with
X2-year cART use (PR vs non-users¼ 0.68, 95% CI: 0.53–0.88)
(data not shown).
Detection of CIN2/3, according to CD4 count (overall and
stratified by cART use) and cART use is shown in Table 4. Cervical
intraepithelial neoplasia 2/3 presence increased significantly from
17.2% in women with CD4 count X500 cellsml 1 to 30.7% in
women with CD4 count o250 cellsml 1 (PR¼ 1.66; 95% CI: 1.05–
2.64). Stratification by cART use showed, however, that the inverse
association between CD4 count and CIN2/3 prevalence was
restricted to non-cART users (PR¼ 4.23; 95% CI: 1.27–14.07).
Use of cART was not associated with CIN2/3 detection.
Table 5 shows the age-specific detection of CIN1 and CIN2/3
among hrHPV-positive women, which is equivalent to the clinical
PPV of hrHPV testing for the corresponding diagnoses. The
detection of CIN1 decreased from 40.0% in women o35 years to
22.2% in women X45 years (Ptrend PR¼ 0.122). Conversely, the
proportion of CIN2/3 in hrHPV-positives increased significantly
from 28.9% below age 35 to 53.3% at age 45 or older (PR¼ 1.71;
95% CI: 1.10–2.66). CIN2/3-to-CIN1 ratio increased, among
hrHPV-positive women, therefore, from 0.7 below age 35 to 2.4
at age 45 years or older.
Table 2 PRs for the presence of hrHPV infection, and corresponding
95% CIs according to selected characteristics among 498 HIV-positive
women (Kenya, 2009)
hrHPV infection
Characteristics Total n (%) PRa (95% CI)
All women 498 262 ( 52.6)
Age group (years)
o30 62 38 (61.3) 1
30–34 101 54 (53.5) 0.87 (0.67–1.14)
35–39 123 65 (52.9) 0.86 (0.67–1.12)
40–44 109 54 (49.5) 0.81 (0.61–1.06)
X45 103 51 (49.5) 0.81 (0.61–1.07)
w1
2 for trend 2.23 (P¼ 0.136)
Education
None-Primary 106 63 (59.4) 1
Secondary 253 137 (54.2) 0.93 (0.76–1.12)
Higher education 139 62 (44.6) 0.74 (0.58–0.95)
w1
2 for trend 5.87 (P¼ 0.015)
Marital status
Single 118 66 (55.9) 1.07 (0.86–1.31)
Married 215 110 (51.2) 1
Divorced/separated 76 45 (59.2) 1.21 (0.95–1.53)
Widowed 89 41 (46.1) 0.94 (0.71–1.24)
Lifetime sexual partners
1 161 91 (56.5) 1
2 129 76 (58.9) 1.05 (0.86–1.28)
X3 95 46 (48.4) 0.86 (0.67–1.10)
Missing 113 49 (43.4) 0.78 (0.61–1.01)
w1
2 for trendb 1.03 (P¼ 0.311)
Recent sexual partners (o3 months)
0 179 88 (49.2) 1
1þ 309 167 (54.1) 1.06 (0.88–1.29)
Missing 10 7 (70.0) —
Hormonal contraceptive use
Never 167 81 (48.5) 1
Everc 331 181 (54.7) 1.15 (0.95–1.38)
Number of pregnancies
0 39 19 (48.7) 0.88 (0.61–1.26)
1 109 61 (56.0) 1
2 152 77 (50.7) 0.97 (0.76–1.24)
X3 198 105 (53.0) 1.02 (0.81–1.29)
w1
2 for trend 0.52 (P¼ 0.471)
Abbreviations: CIs¼ confidence intervals; HIV¼ human immunodeficiency virus;
hrHPV¼ high-risk human papillomavirus; PRs¼ prevalence ratios. aAdjusted for age,
as appropriate. bMissing data excluded. cOral, injectable, or Norplant contraceptives.
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DISCUSSION
Human immunodeficiency virus-positive women in our present
study had a very high prevalence of HPV infections (68.7%),
notably hrHPV type (52.6%), and multiple infections (40.2%). The
availability of cervical biopsy in all study participants led to the
detection of CIN2/3 in 37.5% of hrHPV-positive women. Cervical
intraepithelial neoplasia 2/3 detection and, hence, the PPV of
hrHPV-positivity, increased with age. High CD4 count and
prolonged cART use were significantly associated with lower
prevalence of hrHPV infection. CD4 count was inversely related to
CIN2/3 detection only among women who had never used cART
and cART use had no clear impact on CIN2/3 presence.
Elevated prevalence of HPV (50% or more) and high-grade
lesions were consistently reported in HIV-positive women in SSA
(Clifford et al, 2006; Singh et al, 2009; Firnhaber et al, 2010; Djigma
et al, 2011; Tobian et al, 2011), as well as in high-resource
countries (Clifford et al, 2006; Paramsothy et al, 2009). We
Table 3 PRs for the presence of hrHPV infections and corresponding 95% CIs by CD4 counts and cART use among 497a HIV-positive women (Kenya,
2009)
cART non-users (n¼ 122) cARTo2 years (n¼ 171) cARTX2 years (n¼ 204) All (n¼ 497)
hrHPV hrHPV hrHPV hrHPV
n n (%) PRb (95% CI) n n (%) PRb (95% CI) n n (%) PRb (95% CI) n n (%) PRb (95% CI)
CD4 (cells ml 1)
X500 35 21 (60.0) 1 25 11 (44.0) 1 82 33 (40.2) 1 142 65 (45.8) 1
250–499 57 26 (45.6) 0.83 (0.55–1.26) 75 44 (58.7) 1.32 (0.81–2.15) 93 41 (44.1) 1.10 (0.77–1.57) 225 111 (49.3) 1.09 (0.87–1.37)
o250 30 24 (80.0) 1.51 (1.02–2.25) 71 47 (66.2) 1.48 (0.92–2.38) 29 15 (51.7) 1.29 (0.83–2.02) 130 86 (66.2) 1.46 (1.18–1.82)
w1
2 for trend 5.03 (P¼ 0.025) 2.98 (P¼ 0.084) 1.19 (P¼ 0.275) 12.84 (Po0.001)
All 122 71 (58.2) 1 171 102 (59.7) 1.04 (0.85–1.26) 204 89 (43.6) 0.77 (0.61–0.96) 497 262 (52.7) 6.52 (P¼ 0.011)c
Abbreviations: cART¼ combination antiretroviral therapy; CIs¼ confidence intervals; HIV¼ human immunodeficiency virus; hrHPV¼ high-risk human papillomavirus; PRs¼
prevalence ratios. aOne missing cART information excluded. bAdjusted for age. cw1
2 for linear trend in PRs by cART use.
Table 4 PRs for the presence of CIN2/3 and corresponding 95% CIs by CD4 counts and cART use among 470a HIV-positive women (Kenya, 2009)
cART non-users (n¼120) cARTo2 years (n¼ 160) cARTX2 years (n¼ 190) All (n¼ 470)
CIN2/3 CIN2/3 CIN2/3 CIN2/3
n n (%) PRb (95% CI) n n (%) PRb (95% CI) n n (%) PRb (95% CI) n n (%) PRb (95% CI)
CD4 (cells ml 1)
X500 34 3 (8.8) 1 23 6 (26.1) 1 77 14 (18.2) 1 134 23 (17.2) 1
250–499 56 13 (23.2) 2.99 (0.91–9.80) 71 19 (26.8) 0.93 (0.43–2.05) 85 20 (23.5) 1.18 (0.64–2.18) 212 52 (24.5) 1.37 (0.88–2.14)
o250 30 11 (36.7) 4.23 (1.27–14.07) 66 20 (30.3) 1.01 (0.46–2.22) 28 7 (25.0) 1.25 (0.56–2.77) 124 38 (30.7) 1.66 (1.05–2.64)
w1
2 for trend 6.23 (P¼ 0.013) 0.02 (P¼ 0.903) 0.38 (P¼ 0.540) 4.70 (P¼ 0.030)
All 120 27 (22.5) 1 160 45 (28.1) 1.18 (0.78–1.79) 190 41 (21.6) 0.88 (0.57–1.35) 470 113 (24.0) 0.66 (P¼ 0.416)c
Abbreviations: cART¼ combination antiretroviral therapy; CIs¼ confidence intervals; CIN¼ cervical intraepithelial neoplasia; HIV¼ human immunodeficiency virus; hrHPV¼
high-risk human papillomavirus; PRs¼ prevalence ratios. aExcluding 27 inadequate histologies and one missing cART information. bAdjusted for age. cw12 for linear trend in PRs by
cART use.
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Figure 1 Age-specific prevalence of HPV (classified hierarchically into HPV16 and/or 18; high-risk types but not HPV 16/18; and low-risk types only), and
multiple HPV infections (Kenya, 2009).
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compared the prevalence of selected HPV types in HIV-positive
women in our study with that in women from the general
population in Africa, using a large meta-analysis (Guan et al,
2012). The more than two-fold higher HPV prevalence among
histologically normal women in our study than in Guan et al was
mainly accounted for by hr types other than HPV16. Our findings
are consistent with a report from the two US cohorts in which the
prevalence and incidence of HPV16 in HIV-positive women was
more weakly associated with a woman’s immune status than that
of other hrHPV types (Strickler et al, 2003). Human papilloma-
virus 16 was the most frequently detected type (29.4%) in HPV-
positive CIN2/3 lesions in our present study in agreement with the
findings of the meta-analysis for high-grade lesions in Africa
(30.3%) (Guan et al, 2012). The proportion of HPV18 in HPV-
positive women with different histological findings was well
comparable in our study and the meta-analysis (e.g., 10.6% and
9.2%, respectively in women with high-grade cervical lesions)
(Guan et al, 2012). Human papillomavirus 16 was found in 23% of
high-grade intraepithelial lesions among HIV-positive women in
Rwanda (Singh et al, 2009), and 42% in South Africa (Firnhaber
et al, 2010).
In our present study, the prevalence of any HPV type, hr types,
and the proportion of multiple HPV infections was similar across
all the age groups in agreement with a few studies of the general
female populations in SSA (Keita et al, 2009; De Vuyst et al, 2010;
Clarke et al, 2011) and among HIV-positive women in SSA and
high-resource countries.
We found no significant risk factors for hrHPV-positivity except
for a moderate negative association with educational level.
Although self-reported sexual behaviour has serious limitations,
a lack of association of hrHPV-positivity with the number of
lifetime or recent sexual partners may be explained by a stronger
role of impaired clearance and reactivation than increased HPV
acquisition in HIV-positive women (Strickler et al, 2003). It is also
possible that influence of sexual behaviour is obscured by the
extremely high hrHPV prevalence in HIV-positive women.
Twenty-three percent of women did not provide information
on lifetime number of sexual partners. They did not have,
however, an increased risk for hrHPV infection (PR¼ 0.78; 95%
CI: 0.61–1.01).
Low CD4 count was associated with higher positivity for hrHPV
and multiple HPV infections, consistently among cART users and
non-users, in agreement with a few previous reports (Strickler
et al, 2005; Denny et al, 2008; Singh et al, 2009; Firnhaber et al,
2010). To date, only few studies have been able to show an impact
of cART on HPV infection (Paramsothy et al, 2009; Bratcher and
Sahasrabuddhe, 2010; Minkoff et al, 2010). Two years cART
treatment or longer was also associated with lower prevalence of hr
and multiple HPV infections in our study. The need for relatively
long-duration cART use to diminish HPV burden may derive from
the fact that immune reconstitution after initiation of cART occurs
through different phases. It starts mainly with an immediate re-
distribution of memory T-cells from the lymphoid tissues and
it is followed by an expansion of naive T-cells from the thymus
that may be active against new pathogens. The latter process
takes months to years after cART initiation (Corbeau and Reynes,
2011).
CD4 count was inversely associated with CIN2/3 presence only
in women who had never been on cART. In fact, cART use rapidly
modifies CD4 count and makes current CD4 uninformative in
respect to the past burden of immunosuppression. Lack of clear
beneficial impact of cART on CIN2/3 detection in our study may
suggest that immune reconstitution by cART was not able to
prevent or reverse the development of CIN2/3 possibly because it
was not established sufficiently early in time after HPV infection.
Unfortunately, our study did not include information on CD4
count at the start of cART and adherence with treatment.
Concerns were expressed on the lack of specificity of HPV
testing in HIV-positive women, due to very high hrHPV
prevalence. We explored, therefore, for the first time in HIV-
positive women, the PPV of hrHPV-positive results for CIN2/3 in
the different age groups. The PPV for CIN2/3 was high across all
the age groups but it reached 53% in women aged 45 years or older
as CIN2/3 accumulate over time in inadequately screened women
(Gage et al, 2012). High PPV demonstrates the effectiveness and
potential cost-effectiveness (Vanni et al, 2012) of HPV testing HIV-
positive women despite low test specificity (Kuhn et al, 2010;
Giorgi-Rossi et al, 2012). A modelling study showed that, at a cost
of 13 USD per test, yearly screening using the HPV hybrid-
capture2 test followed by cytology was very cost-effective, in
respect to the current yearly cytology screening in HIV-positive
women in Brazil (Vanni et al, 2012). The advent of a low-cost rapid
HPV test in the near future will favour the cost-effectiveness of
HPV testing even more.
The greatest strength of our present study is the availability of a
biopsy for all women, regardless of cytological findings. An
additional strength is the use of a well-validated and widely used
HPV test (Clifford et al, 2006; Guan et al, 2012) whose findings
were ignored by the local pathologist. Weaknesses include the
cross-sectional nature of our present findings that did not allow to
investigate the effects of CD4 count and cART on HPV infection
and CIN2/3 longitudinally. Unfortunately we were also not able to
collect information on either CD4 at the beginning of cART or
adherence to treatment, that is, information that would have
especially helped interpreting our findings on cART and CIN2/3
prevalence. Finally, although we had a sufficiently large number of
HIV-positive women to describe HPV type distribution overall and
by CIN presence, some potentially informative subgroups were
small (e.g., women with CD4 X500 cells ml 1).
In conclusion, the burden of hrHPV and CIN2/3 in HIV-positive
women in Kenya was high and it was related to immunosuppression
level. Combination antiretroviral therapies (X2 year) use had a
favourable effect on hrHPV prevalence but antiretroviral treatment
in our study population may have been started too late to prevent or
reverse CIN2/3. Timely initiation of cART may ultimately decrease
cervical cancer in HIV-positive women. Access to HPV vaccination
and cervical screening using HPV testing in SSA are needed to
reduce cervical cancer among HIV-positive women.
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